EUROIMMUN

Reagena is a distributor for EUROIMMUN products in Finland.

ELW ELISA

As one of the leading manufacturers of medical laboratory diagnostics worldwide, EUROIMMUN stands for innovation. More than 3,400 employees in 17 countries develop, produce and sell test systems to support the diagnosis of diseases, as well as software and automation solutions for the performance and evaluation of these tests. Laboratories in over 140 countries use EUROIMMUN products for the diagnosis of autoimmune and infectious diseases as well as allergies, and to perform genetic analyses.

The company was founded in 1987 from the University of Lübeck (Schleswig-Holstein, Germany). Since 2018, the US American company PerkinElmer, Inc. has been the sole shareholder of EUROIMMUN. PerkinElmer is an international leader in medical and biotechnology. Further information can be found here.

Core disciplines:

  • Automation
  • Veterinary diagnostics
  • Molecular genetic diagnostics
  • Antigen detection
  • Allergy diagnostics
  • Autoimmune

 

Petri Muranen

Product Specialist

EUROIMMUN products and Beckman Coulter Diagnostics microbiology and immunoassay

+358 40 680 0945
petri.muranen@reagena.com

Contact me

Read more:

Reagena logo Posts

Reagena 35 years – Decades of Reliable Diagnostics

Now, when a new year has begun, it is good time to look at the past and envision the future. For us at Reagena, 2022 was the year of celebration...

Reagena logo Posts

Up to Date Information from the National Near Patient Testing Days

To examine a patient with an infection, specialized laboratory diagnostics are often required, which can also be done with point-of-care tests....

Posts

Greetings from the ICLB 2022

In the beginning of September Reagena team attended the International Conference on Lyme Borreliosis and other Tick-borne diseases (ICLB), which...

Posts

The importance of rapid tests will increase in the future

This year's AACC Annual Scientific meeting + Clinical Lab Expo showed just how significant role rapid tests play in the IVD market. In the last...